United States News Todas as matérias

AEVEX Corp. (NYSE:AVEX) completed its acquisition of BlackSea Technologies, adding unmanned surface and subsea vessel capabilities to its autonomous defense systems business.

Inhibrx Biosciences (NASDAQ:INBX) reported Phase 2 HexAgon trial results showing INBRX-106 combined with pembrolizumab achieved a 48.3% confirmed objective response rate in first-line head and neck cancer patients.

Abbott (NYSE:ABT) received U.S. FDA approval for its TactiFlex Duo Ablation Catheter, Sensor Enabled, a device designed to treat atrial fibrillation using pulsed field ablation and radiofrequency energy technologies.

AstraZeneca (NASDAQ:AZN) reported Phase III OBERON and TITANIA trial results showing tozorakimab reduced moderate and severe COPD exacerbations across broad patient populations while patients remained on standard inhaled treatment.

enGene Therapeutics (NASDAQ:ENGN) reported regulatory and clinical progress for detalimogene, including plans for a U.S. FDA pre-BLA meeting and initiation of a Biologics License Application submission in the fourth quarter of 2026.

IonQ (NYSE:IONQ) expects full-year 2026 revenue of $450 million–$460 million following its acquisition of SkyWater Technology, with the outlook including SkyWater’s contribution from July 31 through December 31, 2026.

Adlai Nortye (NASDAQ:ANL) dosed the first patient in Australia in a global Phase I trial evaluating AN4035, an antibody-drug conjugate designed to treat CEACAM5-enriched RAS-addicted solid tumors.

Bristol Myers Squibb (NYSE:BMY) reported positive Phase 2 QUINTESSENTIAL trial results for arlocabtagene autoleucel (arlo-cel) in adults with quadruple-class exposed relapsed and refractory multiple myeloma.

United Natural Foods (NYSE:UNFI) reported fiscal 2026 net sales of $31.2 billion, down 2% year over year, while adjusted EBITDA increased 27% to $701 million.

ABM (NYSE:ABM) reported fiscal third-quarter 2026 revenue of $2.32 billion, up 4.2% year over year, with net income rising to $49.7 million from $41.8 million in the prior-year period.

Pharvaris (NASDAQ:PHVS) reported Phase 3 CHAPTER-3 results showing once-daily oral deucrictibant XR reduced hereditary angioedema attack rates by 83% versus placebo across all HAE types after 24 weeks.

Bullish (NYSE:BLSH) reported August 2026 trading metrics showing total trading volume of $42.5 billion, up from July 2026 but below the same month in 2025.

Solaris Energy Infrastructure (NASDAQ:SEI) raised its fourth-quarter 2026 adjusted EBITDA guidance to $145 million–$180 million as the company expands power infrastructure to support rising electricity demand from data centers.

Canaan (NASDAQ:CAN) reported second quarter 2026 revenue of US$31.9 million, down from US$62.7 million in the first quarter and US$100.2 million in the same period of 2025.

Circle Internet Group (NYSE:CRCL) agreed to acquire Singapore-based B2B cross-border payments infrastructure company Tazapay, expanding its USDC payment network with a platform processing more than $25 billion in annualized payment volume.

Roivant (NASDAQ:ROIV) reported Phase 2 PHocus trial results showing mosliciguat reduced pulmonary vascular resistance by 56.3% v

Gamehaus Holdings (NASDAQ:GMHS) reported fiscal year 2026 revenue of US$104.7 million, down 11.4% from the previous year, while net income increased slightly to US$3.9 million.

Belite Bio (NASDAQ:BLTE) submitted a New Drug Application in Japan for tinlarebant, an investigational once-daily oral therapy for Stargardt disease type 1, under Japan’s Sakigake Designation System.

Beam Therapeutics (NASDAQ:BEAM) reported updated Phase 1/2 data for BEAM-302 showing increased alpha-1 antitrypsin levels and reductions in mutant Z-AAT among patients with alpha-1 antitrypsin deficiency.

Waterdrop (NYSE:WDH) reported second quarter 2026 net operating revenue of RMB1,448.2 million, up 72.8% year-over-year, and announced a US$0.03 per ADS dividend alongside a new US$50 million share repurchase program.

Lithia & Driveway (NYSE:LAD) acquired Rockwall Hyundai in Rockwall, Texas, adding an estimated $75 million in annualized revenue and expanding its dealership network in the Dallas-Fort Worth market.

Hang Feng Technology Innovation (NASDAQ:FOFO) reported first half 2026 revenue of $362,511 and a net loss of $553,033 as corporate management consulting revenue declined during a strategic shift toward real-world asset initiatives.

Brent crude and West Texas Intermediate crude prices rose to multi-week highs on Tuesday as escalating U.S.-Iran tensions increased concerns about prolonged disruptions to Middle East oil supplies.

Upstream Bio (NASDAQ:UPB) reported Phase 2 VALIANT trial results showing its verekitug treatment reduced annualized asthma exacerbation rates by 56% versus placebo in adults with severe asthma.